Author(s):
Abhishek B. Wakade, Shital T. Waghmode, Omkar A. Wagh, Uniket M. Gosavi
Email(s):
wakadeabhishek45@gmail.com
DOI:
10.52711/2349-2988.2025.00013 
Address:
Abhishek B. Wakade1, Shital T. Waghmode2, Omkar A. Wagh3, Uniket M. Gosavi4
1-3Student, JBVP Vidyaniketan Collage of Pharmacy, Lakhewadi.
4Assistant Professor, Dept. of Pharmaceutical Quality Assurance, JBVP Vidyaniketan Collage of Pharmacy, Lakhewadi.
*Corresponding Author
Published In:
Volume - 17,
Issue - 1,
Year - 2025
ABSTRACT:
The most common method of taking medication is orally, despite several drawbacks like as intentional absorption and a delayed beginning of effect. This can be resolved by administering the medication as an effervescent tablet, which is a liquid form. The diclofenac sodium effervescent tablet formulation study uses a wet granulation technique. Because they are simple to use and have a quick start to working, effervescent pills are growing in favour. One of these NSAIDs, diclofenac sodium (DS), has a strong affinity for the enzymes cyclooxygenase (COX)-2, which breaks down arachidonic acid. Neuropathic pain can be treated with this medication. Diclofenac is linked to significant adverse effects on the kidneys heart and stomach that are dose dependent. Many diclofenac-containing medication items have been created since its first in 1973 with the intention of enhancing patient convenience, tolerability, and efficacy.
Cite this article:
Abhishek B. Wakade, Shital T. Waghmode, Omkar A. Wagh, Uniket M. Gosavi. A Review Article on Effervescent Tablet of Diclofenac Sodium. Research Journal of Science and Technology. 2025; 17(1):89-8. doi: 10.52711/2349-2988.2025.00013
Cite(Electronic):
Abhishek B. Wakade, Shital T. Waghmode, Omkar A. Wagh, Uniket M. Gosavi. A Review Article on Effervescent Tablet of Diclofenac Sodium. Research Journal of Science and Technology. 2025; 17(1):89-8. doi: 10.52711/2349-2988.2025.00013 Available on: https://rjstonline.com/AbstractView.aspx?PID=2025-17-1-13
REFERANCE:
1. Advankar A, Maheshwari R, Tambe V, Todke P, Raval N, Kapoor D, etal. Specialized tablets: Ancient history to modern developments. In: Drug Delivery Systems. Elsevier; 2019. p. 615-64. https://doi.org/10.1016/B978-0-12-814487-9.00013-2
2. Rudnic: Tablet dosage forms - Available from:https://scholar.google.com/scholar_lookup?title=Tablet%20dosage%20forms&author=E.M.%20Rudnic&publication_year=2002
3. İpci K, Öktemer T, Birdane L, Altıntoprak N, Bayar Muluk N, Passali D, et al. Effervescent tablets: a safe and practical delivery system for drug administration. ENT Updates. 2016 Apr 1; 46-50. https://doi.org/10.2399/jmu.2016001009
4. Viscosity. In: Indian Pharmacopoeia. The Indian Pharmacopoeia Commission, Indian Pharmacopoeia Laboratory, Govt. of India, Ministry of Health & Family Welfare; 2018. p. 2523.
5. Sendall:0 Effervescent tablets - Available from: https://scholar.google.com/scholar_lookup?title=Effervescent%20tablets&journal=Pharm.%20J.&volume=230&pages=289294&publication_year=1983&author=Sendall%2CF.%20E.%20J.&author=Staniforth%2CJ.%20N.&author=Rees%2CJ.%20E.&author=Leatham%2CM.%20 J.
6. Eichman Jonathan, Robinson Joseph. Mechanistic studies on effervescent-induced permeability enhancement. Pharm Res. 1998; 15(6):925-30. https://doi.org/10.1023/A:1011936901638
7. Rani R, Masoanl K, Sherry. A recent updated review on effervescent tablet. International journal of creative research thoughts. 2020; 8(4):3928-35. Available from: www.ijcrt.org
8. Patel SG, Siddaiah M. Formulation and evaluation of effervescent tablets: a review. Journal of Drug Delivery and Therapeutics. 2018 Nov 15; 8(6):296-303. https://doi.org/10.22270/jddt.v8i6.2021
9. Biranje S, More A, Shangrapawar TP, Bhosale PDEA A. A Review on Formulation and Evaluation of Effervescent Tablet. Int J Pharm Pharm Res. 2021; 21(3):476-86.
10. BG P, O M. Concept, Manufacturing and Characterization of Effervescent Tablets: A Review. SunText Review of Pharmaceutical Sciences. 2021; 02(01). https://doi.org/10.51737/2766-5232.2021.010
11. Rani Ms. Review on Introduction to Effervescent Tablets and Granules. Kenkyu Journal of Pharmacology. 2020; 6:1-11. https://doi.org/10.12928/pharmaciana.v11i2.20873
12. Juarez-Enriquez E, Olivas GI, Zamudio-Flores PB, Ortega-Rivas E, Perez-Vega S, Sepulveda DR. Effect of water content on the flowability of hygroscopic powders. J Food Eng. 2017 Jul 1; 205:12-7. https://doi.org/10.1016/j.jfoodeng.2017.02.024
13. Apostolopoulos D, Fusi R. Prediction of moisture barrier requirements for an effervescent single serve aspartame sweetened tablet. Development in food science. 1995; 37:1119-32. https://doi.org/10.1016/S0167-4501(06)80223-2
14. Agyilirah GA, Green M, DuCret R, Banker GS, Evaluation of the gastric retention properties of a cross-linked polymer coated tablet versus those of a non-disintegrating tablet, International Journal of Pharmaceutics, 1991; 75: 241–47.
15. Mohrle, R., Liberman, L, Schwartz L, Pharmaceutical Dosage Form, Vol. 1, Marcel Decker Inc., New York, 2005; 285- 292.
16. Lachman L, Liberman HA, Kanig JL. The theory and practice of industrial pharmacy. 3rd ed. Philadelphia: lea and febiger; 1986.
17. Swarbrick J, Boylan JC. Encyclopedia of pharmaceutical technology. New York: Marcel Dekker; 2002
18. Harald S, Effervescent Dosage, Pharmaceutical Technology Europe, 2003; 15(4): 25–28.
19. Srinath KR, “Formulation and Evaluation of Effervescent tablets of Paracetamol”, International Journal of Pharmaceutical Research & Development, 2011; 3(3):76-104.
20. Indian Pharmacopoeia, Government of India Ministry of Health and Family Welfare. Delhi: Controller of Publications 1996; 2: 35, 448, 554.
21. Howard CA, Lloyd A, Nocholas and Popovich, “Effervescent granules”8th edition “Pharmaceutical Dosage From and Drug Delivery” International Student Edition.-2000, 172-178.
22. Shimodaira S, Quality Verification of Dendritic Cell-Based Cancer Vaccine. Pharm Anal Acta, 2016; 7:467.
23. Hassali MA, Role of Pharmacists in Health Based Non-Governmental Organizations NGO: Prospects and Future Directions, Pharm Anal Acta. 2016; 7:467.
24. Vergeire DG, Usefulness of Cost Acta, 2016; 7:456.
25. Wang C, Application of In Vitro Models in Developmental Neurotoxicity and Pharmaceutics Research, Journal of Molecular Pharmaceutics & Organic Process Research, 2015;3:122-128..
26. Lyubchenko YL, Nanoimaging for Molecular Pharmaceutics of Alzheimer’s and other Neurodegenerative Disorders, Journal of Molecular Pharmaceutics & Organic Process Research, 2013;1:107-111.
27. Foldvari M, Nanopharmaceutics Innovations in Gene Therapy: Moving Towards Non-Viral and Non-Invasive Delivery Methods. J Nanomedine Biotherapeutic Discovery. 2014; 4:135.
28. Maurya SD, Rawal RK, Jha S, Chauhan PS, Kumar A, Drug Loaded Beads: Current Status, American Journal of PharmTech Research, 2013; 3 (1): 331-337.
29. Sallam A, Bioequivalence of Two Oral Formulations of Modafinil Tablets in Healthy Male Subjects under Fed and Fasting Conditions. Journal of Bioequivalence Availability. 2015; 7:63-67.
30. Agatonovic KS, Biorelevant Dissolution Studies of Pioglitazone HCL Immediate Release Tablets and the Determination of an In Vitro In Vivo Correlation, Journal of Bioequivalence Availability, 2015; 7:086-089
31. Prabhakar C, Krishna K. A review on efferevesent tablets. International Journal of Pharmacy and Technology. 2011; 3:704-12. Available from: https://www.researchgate.net/publication/286848680 A review on efferevesent tablets.
32. Vasim SM. Effervescent Mixture Based Solid Dispersion a Novel Approach for Solubility Enhancement. Research J Pharm and Tech. 2011; 4(11):1682-6.
33. Patel Salim G., Siddaiah M., Journal of Drug Delivery and Thera-peutics 2018; 8(6): 296-(303 Formulation and Evaluation of Effervescent tablets: A Review ISSN 2250-1177, Page No.299.
34. Lacheman or Liebermans 4th Edition the theory and practice of Industrial Pharmacy Published by CBS Publisher and Distributors PVT LTD. Page No. (468)
35. Dash RT, Verma P. Matrix: An approach towards oral extended release drug delivery. IJPPR. 2012; 2(2): 12-24
36. Kanwar N., Kumar R., Sarwal A. and Sinha V.R., Preparation and evaluation of floating tablets of pregabalin. Drug Development and Industrial Pharmacy, 42(4): 1-7, (2015)
37. Katariya C. and Roy A., Floating Drug Delivery System for Analgesic - A Review. International Journal of Pharmaceutical Sciences Review and Research, 43(2): 1-4, (2017)
38. Sun Z, Ya N, Adams RC, Fang FS. Particle size specifications for solid oral dosage forms: a regulatory perspective. Am PharmRev. 2010;13(4):70–3.
39. Manjunatha K.M., Ramana M.V. and D Satyanarayana D., Design and evaluation of diclofenac sodium controlled drug delivery system. Indian Journal of Pharmaceutical Science, 69(3): 384-389, (2007)
40. Tripathi K.D., Essentials of medical pharmacology, 6th edition, Jaypee brothers, medical publisher (P) Ltd., New Delhi, 2008, 184-206.
41. Rang H.P., De M.M., Ritter J.M., Flower R.J., Rang and Dale's pharmacology, 6thEdition, Churchill Livingstone Elsevier, 2007, 227-233.
42. Kornblurn S.S., Batopak S.W., J. Pharm Sci, 1993, 82 (1), 43-49.
43. Kouchak M. and Atyabi F., Ion-exchange, an Approach to Prepare an Oral Floating Drug Delivery System for Diclofenac. Iranian Journal of Pharmaceutical Research, 2: 93-97, (2004)
44. Swain R.P., Pendela S. and Panda S., Formulation and Evaluation of Gastro-bilayer Floating Tablets of Simvastatin as Immediate Release Layer and Atenolol as Sustained Release Layer. Indian Journal of Pharmaceutical Sciences, 78(4): 458-468, (2016)
45. Srinath KR, Chowdary C.P., Palanisamy P. Formulation and Evaluation of Effervescent tablets of Paracetamol., Int. J Pharma Research 2011; 3(3) 12 May 2011 et. Al, uprd 2011 Page No 77.
46. Andersson T, Bredberg E, Lagerstrom PO, Naesdal J, Wilson I.Lack of drug-drug interaction between three different non-steroidal anti-inflammatory drugs and omeprazole. Eur J ClinPharmacol. 1998;54(5):399–404.
47. Sugano K, Kinoshita Y, Miwa H, Takeuchi T, Esomeprazole NSAID Preventive Study Group. Safety and efficacy of long-term esomeprazole 20 mg in Japanese patients with a history of peptic ulcer receiving daily non-steroidal anti-inflammatory drugs. BMC Gastroenterol. 2013;13:54.
48. Chan FK, Lanas A, Scheiman J, Berger MF, Nguyen H, Goldstein JL. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet. 2010;376(9736):173–9.
49. Massimo Claar G, Monaco S, Del Veccho Blanco C, Capurso L, Fusillo M, Annibale B. Omeprazole 20 or 40 mg daily for healing gastroduodenal ulcers in patients receiving non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther.1998;12(5):463–8.
50. The Nonsteroidal Anti-Inflammatory Drugs: Treating Osteoarthritis and Pain Comparing Effectiveness, Safety, and Price 2013. Available from :https://www.consumerreports.org/health/resources/pdf/best-buy drugs/Nsaids2. pdf. Accessed 24 Mar 2014.
51. Davies NM, Anderson KE. Clinical pharmacokinetics of diclofenac. Therapeutic insights and pitfalls. Clin Pharmacokinet.1997;33(3):184–213.
52. Laine L, Connors LG, Reicin A, Hawkey CJ, Burgos-Vargas R, Schnitzer TJ, et al. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology. 2003;124(2):288–92.
53. Wallace JL. Mechanisms, prevention and clinical implicationsof nonsteroidal anti-inflammatory drug-enteropathy. World J Gastroenterol. 2013;19(12):1861–76.
54. Adeyeye, C.M. and Li, P.K., 1990. Diclofenac sodium. In Analytical profiles of drug substances (Vol. 19, pp. 123-144). Academic Press.
55. Scholer, D.W., Ku, E.C., Boettcher, I. and Schweizer, A., 1986. Pharmacology of diclofenac sodium. The American journal of medicine, 80(4), pp.34-38.
56. Newbould BB: Chemotherapy of arthritis induced in rats by mycobacterial adjuvant. Br J Pharmacol 1963; 21: 127-136
57. Schweizer A, Brom R: Differentiation of peripheral and central effects of analgesic drugs. Int J Tissue React 1965; 7: 79-63.
58. H.L. White, and A.T. Glassman, Prostaglandins, L 123 (1 974)
59. Adeyeye, C.M. and Li, P.K., 1990. Diclofenac sodium. In Analytical profiles of drug substances (Vol. 19, pp. 123-144). Academic Press.
60. Todd, P.A. and Sorkin, E.M., 1988. Diclofenac sodium: a reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs, 35, pp.244-285.
61. Plavsic, F., & Culig, J. (1985) Human Toxicol. 4, 317-322
62. Shen TY: Synthesis and biological activity of some indomethacin analogs. In Garattini S, Dukes MNG, eds. International Symposium on Non-Steroidal Drugs, Milan, 1964. International congress series No. 82. Amsterdam: Excerpta Medica Foundation, 1985: 13.
63. Gund P, Shen TY: A model for the prostaglandin synthetase Cyclooxygenation site and its inhibition by anti-inflammatory Aryl acetic acids. J Med Chem 1977; 20: 1148-l 152.
64. Haas G, Rossi A: United States Patent 4057573 (to CIBAGEIGY), 1974.
65. Hobbs DC, Twomey TM: Piroxicam pharmacokinetics in man: Aspirin and antacid interaction studies. J Clin Pharmacol 1978; 19:. 270-281.
66. Brogden, R.N., Heel, R.C., Pakes, G.E., Speight, T.M. and Avery, G.S., 1980. Diclofenac sodium: a review of its pharmacological properties and therapeutic use in rheumatic diseases and pain of varying origin. Drugs, 20, pp.24-48.
67. P. D. Fowler, M. F. Shadforth, P. R. Crook, V. A. Euro, J. Clin. Pharmacol., i& 389 (1983).
68. W. Reiss, H. Sterlin, P. Degen, J. W. Faigle, A. Ge'rardin , J. Moppert, A. Sallman, K. Schmid, A. Schweizer, M. Sulc, W. Thesbald and J. Wagner, &and. J. Rheumafology, Supp 22: 17-29 (1978).
69. Pirard D, Vereecken P, Mélot C, Heenen M. Three percent diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses: a meta-analysis of the recent studies. Arch Dermatol Res. 2005 Nov;297(5):185-9.
70. Tampucci S, Carpi S, Digiacomo M, Polini B, Fogli S, Burgalassi S, Macchia M, Nieri P, Manera C, Monti D. Diclofenac-Derived Hybrids for Treatment of Actinic Keratosis and Squamous Cell Carcinoma. Molecules. 2019 May 09;24(9)
71. Standing JF, Savage I, Pritchard D, Waddington M. Diclofenac for acute pain in children. Cochrane Database Syst Rev. 2009 Oct 07;(4):CD005538.
72. Monita Thakare and Kamalinder K. Singh Preparation and Evaluation of diclofenac sodium controlled release tablets using spray drying technology in aqueous system, Indian Journal of Pharmaceutical Sciences.
73. Ahmed M. A. Masaad Formulation and Newly Effervescence diclofenac K tablet., Int-J Pharma Sci. Rev, 48 (January-February) 2018 article No.21 Page No.100
74. T. Comoglu, A. Dogan, S. Comoglu, N. Bascl Formulation and Evaluation of diclofenac potassium fast disintegrating tablets and their clinical application in migraine, Drug Dev Ind Pharma 2011 Mar. National library of medicine.
75. Francesco Cilurzo et al. Diclofenac fast-dissolving film: suppression of bitterness by a taste–sensing system; Drug Dev Ind Pharma 2011 Mar. National library of medicines national centre for biotechnology information.
76. Brater DC. Anti-inflammatory agents and renal function. Semin Arthritis Rheum. 2002;32(3 Suppl 1):33–42.
77. Kuo HW, Tsai SS, Tiao MM, Liu YC, Lee IM, Yang CY. Analgesic use and the risk for progression of chronic kidney disease. Pharmacoepidemiol Drug Saf. 2010;19(7):745–51.
78. Lewis SC, Langman MJ, Laporte JR, Matthews JN, Rawlins MD, Wiholm BE. Dose-response relationships between individual nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a meta-analysis based on individual patient data. Br J Clin Pharmacol. 2002; 54(3): 320–6.
79. Riera-Guardia N, Castellsague J, Calingaert B, Varas-Lorenzo C, Fourrier-Reglat A, Nicotra F, et al. The SOS Project: nonsteroidal anti-inflammatory drugs and upper gastrointestinal complications. Meta-analysis of epidemiological studies. In: International conference on pharmacoepidemiology. Brighton;2010.
80. Salvo F, Fourrier- Reglat A, Bazin F, Robinson P, Riera-Guardia N, Haag M, et al. Cardiovascular and gastrointestinal safety of NSAIDs: a systematic review of meta-analyses of randomized clinical trials. Clin Pharmacol Ther. 2011;89(6):855–66.
81. McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population based controlled observational studies. PLoS Med. 2011;8(9):e1001098.
82. Sinha M, Gautam L, Shukla PK, Kaur P, Sharma S, Singh TP. Current perspectives in NSAID-induced gastropathy. MediatInflamm. 2013; 2013: 258209.
83. Miller TA. Protective effects of prostaglandins against gastric mucosal damage: current knowledge and proposed mechanisms. Am J Physiol. 1983;245(5 Pt 1):G601–23.
84. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivity for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci. 1999; 96(13):7563–8.
85. Patrignani P, Tacconelli S, Bruno A, Sostres C, Lanas A. Managing the adverse effects of nonsteroidal anti-inflammatory drugs. Expert Rev Clin Pharmacol. 2011;4(5):605–21.
86. Patrono C, Baigent C. Nonsteroidal anti-inflammatory drugs and the heart. Circulation. 2014;129(8):907–16.
87. Coxib and traditional NSAID Trialists’ (CNT) Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382(9894):769–79.
88. Yu Y, Ricciotti E, Scalia R, Tang SY, Grant G, Yu Z, et al. Vascular COX-2 modulates blood pressure and thrombosis in mice. Sci Transl Med. 2012;4(132):132ra54.
89. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006; 332(7553): 1302–8.
90. Garcia Rodriguez LA, Tacconelli S, Patrignani P. Role of dosepotency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol. 2008;52(20):1628–36.
91. Kowalski ML, Makowska JS, Blanca M. Hypersensivity to non-steroidal anti-inflammatory drugs (NSAIDs) – classification, diagnosis and management. Allergy 2011; 66: 818-829.
92. Lisowska B, Rell-Bakalarska M, Rutkowska-Sak L. Niesteroidowe leki przeciwzapalne – blaski i cienie. Reumatologia 2006; 44: 106-111.
93. Tatarkiewicz J. Farmakoterapia bólu: wybrane zagadnienia. Część I. Farm Pol 2004; 60: 1001-1006.
94. Zaremba M., Staniszewska A, Niewada M. Niesteroidowe leki przeciwzapalne – fakty, mity i kontrowersje dotyczące ryzyka sercowo-naczyniowego oraz ryzyka powikłań ze strony przewodu pokarmowego. Chor Serca Naczyń 2012; 9: 119-136.
95. Wełnicki M, Mamcarz A. Stosowanie niesterydowych leków przeciwzapalnych u pacjentów kardiologicznych – aktualny stan wiedzy. Kardiol Prakt 2012; 6: 33-37.
96. Ma, W., Quirion, R. Does COX-2-dependent PGE2 play a role in neuropathic pain? Neurosci. Lett. 2008; 437: 165–169.
97. Muja, N., DeVries, G.H. Prostaglandin E(2) and 6-keto-prostaglandin F(1alpha) production is elevated following traumatic injury to sciatic nerve. Glia. 2004; 46: 116–129.
98. Masuko-Hongo, K., Sato, T., Nishioka, K. Chemokines differentially induce matrix metalloproteinase-3 and prostaglandin E2 in human articular chondrocytes. Clin. Exp. Rheumatol . 2005; 23: 57–62
99. Barton, M.J., John, J.S., Clarke, M., Wright, A., Ekberg, J. The glia response after peripheral nerve injury: a comparison between Schwann cells and olfactory ensheathing cells and their uses for neural regenerative therapies. Int. J. Mol. Sci. 2017; 18: 287.
100. Wagner, R., Myers, R.R. Schwann cells produce tumor necrosis factor alpha: expression in injured and non-injured nerves. Neuroscience. 1996; 73: 625–629.
101. Shin, T., Lee, Y., Sim, K.B. Involvement of cyclooxygenase-1 and −2 in the sciatic nerve of rats with experimental autoimmune neuritis. Immunol. Invest. 2003; 32: 123–130.
102. Fu, Q., Hue, J., Li, S. Nonsteroidal anti-inflammatory drugs promote axon re-generation via RhoA inhibition. J. Neurosci. 2007; 27: 4154–4164.
103. Klegeris, A., McGeer, P.L. Cyclooxygenase and 5-lipoxygenase inhibitors protect against mononuclear phagocyte neurotoxicity. Neurobiol. Aging. 2002; 23: 787–794.
104. Mohammadi, R., Hirsaee, M.A., Amini, K. Improvement of functional recovery of transected peripheral nerve by means of artery grafts filled with diclofenac. Int. J. Surg. 2013; 11: 259–264.
105. Camara-Lemarroy, C.R., Guzman-de la Garza, F.J., Barrera-Oranday, E.A., Cabello-Garcia, A.J., Garcia-Tamez, A., Fernandez-Garza, N.E. Celecoxib accelerates functional recovery after sciatic nerve crush in the rat. J. Brachial Plex. Peripher Nerve Inj. 2008; 3: 25.
106. Syriatowicz, J.P., Hu, D., Walker, J.S., Tracey, D.J. Hyperalgesia due to nerve injury: role of prostaglandins. Neuroscience. 1999; 94: 587–594.
107. Cryer, B., Feldman, M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am. J. Med. 1998; 104: 413–421.